Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
anti-CASPR2-encephalitis
anti-LGI1-encephalitis
anti-NMDAR-encephalitis
autoimmune encephalitis
modified Rankin Scale
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
12
2020
accepted:
05
05
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Prospective observations of functional recovery are lacking in patients with autoimmune encephalitis defined by antibodies against synaptic proteins and neuronal cell surface receptors. Adult patients with a diagnosis of autoimmune encephalitis were included into a prospective registry. At 3, 6 and 12 months of follow-up, the patients' modified Rankin Scale (mRS) was obtained. Patients were stratified into three groups according to their antibody (Ab) status: anti-NMDAR-Ab (n=12; group I), anti-LGI1/CASPR2-Ab (n=35; group II), and other antibodies (n=24; group III). A comparably higher proportion of patients in group I received plasma exchange/immunoadsorption and second line immunosuppressive treatments at baseline. A higher proportion of patients in group II presented with seizures. Group III mainly included patients with anti-GABA The different dynamics in the recovery of patients with certain autoimmune encephalitides have important implications for clinical trials. The high proportion of patients with significant disability at 3 months after diagnosis in groups I and III points to the need for improving treatment options. More distinct scores rather than the mRS are necessary to differentiate potential neurological improvements in patients with anti-LGI1-/CASPR2-encephalitis.
Sections du résumé
Background
Prospective observations of functional recovery are lacking in patients with autoimmune encephalitis defined by antibodies against synaptic proteins and neuronal cell surface receptors.
Methods
Adult patients with a diagnosis of autoimmune encephalitis were included into a prospective registry. At 3, 6 and 12 months of follow-up, the patients' modified Rankin Scale (mRS) was obtained.
Results
Patients were stratified into three groups according to their antibody (Ab) status: anti-NMDAR-Ab (n=12; group I), anti-LGI1/CASPR2-Ab (n=35; group II), and other antibodies (n=24; group III). A comparably higher proportion of patients in group I received plasma exchange/immunoadsorption and second line immunosuppressive treatments at baseline. A higher proportion of patients in group II presented with seizures. Group III mainly included patients with anti-GABA
Conclusions
The different dynamics in the recovery of patients with certain autoimmune encephalitides have important implications for clinical trials. The high proportion of patients with significant disability at 3 months after diagnosis in groups I and III points to the need for improving treatment options. More distinct scores rather than the mRS are necessary to differentiate potential neurological improvements in patients with anti-LGI1-/CASPR2-encephalitis.
Identifiants
pubmed: 34093529
doi: 10.3389/fimmu.2021.641106
pmc: PMC8175889
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
641106Informations de copyright
Copyright © 2021 Seifert-Held, Eberhard, Lechner, Macher, Hegen, Moser, Jacob, Puttinger, Topakian, Guger, Kacar, Zoche, De Simoni, Seiser, Oberndorfer, Baumgartner, Struhal, Zimprich, Sellner, Deisenhammer, Enzinger, Reindl, Rauschka, Berger and Höftberger.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Trials. 2020 Jul 8;21(1):625
pubmed: 32641101
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 16;7(1):
pubmed: 31619447
J Autoimmun. 2019 Jan;96:24-34
pubmed: 30595145
Acta Neurol Scand. 2020 Apr;141(4):263-270
pubmed: 31853949
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Trials. 2019 Jun 7;20(1):331
pubmed: 31174586
Neurology. 2013 Oct 22;81(17):1500-6
pubmed: 24068784
Stroke. 2009 Oct;40(10):3393-5
pubmed: 19679846
Ann Neurol. 2017 Jul;82(1):79-92
pubmed: 28628235
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Ann Neurol. 2020 Feb;87(2):313-323
pubmed: 31782181
Front Neurol. 2020 Aug 21;11:852
pubmed: 33162923
Ann Neurol. 2019 Mar;85(3):352-358
pubmed: 30675918
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
BMJ Open. 2016 Nov 3;6(11):e012356
pubmed: 27810972
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Stroke. 1988 May;19(5):604-7
pubmed: 3363593